Simulations Plus Releases ADMET Predictor™ Version 8.5

November 30, 2017

New HTPK Simulation Module allows chemists to screen compound
libraries using novel approach

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of modeling and
simulation solutions for the pharmaceutical, chemicals, and consumer
goods industries, today announced that it has released version 8.5 of
its best-in-class molecular property prediction program, ADMET
Predictor™.

Dr. David Miller, director of ADMET Cheminformatics, said: “Working with
our colleagues in the Simulation Sciences department, we have merged the
mechanistic oral absorption (ACAT™) and minimal PBPK models from GastroPlus™
into this new version of ADMET Predictor to create the High Throughput
Pharmacokinetics (HTPK) Simulation Module. This capability now allows
chemists to seamlessly combine our top-rated QSAR models with virtual
rat and human physiology models to drive lead selection and optimization
activities. This novel approach, which we are terming ‘discovery PBPK,’
should lead to more efficient screening of candidate molecules in early
discovery and improve communication between chemists and DMPK scientists
as compounds progress into early development. Other key improvements in
this version of ADMET Predictor include:

New synthetic difficulty scores to guide strategic resource allocation
during drug design
Improved Ames mutagenicity models – a key toxicity endpoint required
for all drug applications
Optimization of spreadsheet and model-building functions to improve
speed and efficiency
Enhanced command-line capabilities to streamline all major program
operations.”

John DiBella, president of the Lancaster division for Simulations Plus,
added: “We collaborated with a large pharmaceutical company over several
years to implement this new ‘discovery PBPK’ approach using the
standalone GastroPlus and ADMET Predictor programs, submitting several
manuscripts for publication in the process. We always had a goal in mind
to integrate this capability into an easy-to-use application, and we
have now successfully done so. The initial reception has been extremely
positive, and we have received many requests for evaluation. We expect
the new HTPK Simulation Module, as an optional add-on license, and the
other exciting new features in version 8.5 to further the solid sales
gains ADMET Predictor has realized over the past five years as more
chemistry and DMPK departments adopt our unique solutions.”

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and
development software as well as a leading provider of both preclinical
and clinical pharmacometric consulting services for regulatory
submissions. The company is a global leader focused on improving the
ways scientists use knowledge and data to predict the properties and
outcomes of pharmaceutical and biotechnology agents. Our software is
licensed to and used in the conduct of drug research by major
pharmaceutical and biotechnology companies and regulatory agencies
worldwide. Our innovations in integrating new and existing science in
medicinal chemistry, computational chemistry, pharmaceutical science,
biology, and physiology into our software have made us the leading
software provider for physiologically based pharmacokinetic modeling and
simulation. For more information, visit our website at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 – With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like “believe,”
“expect” and “anticipate” mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to
identify and close acquisitions on terms favorable to the Company, and a
sustainable market. Further information on our risk factors is contained
in our quarterly and annual reports as filed with the U.S. Securities
and Exchange Commission.